Business
Announcement on Approval of Subsidiary's Product Dalbavancin for Injection by the U.S. FDA
Announcement on Approval of Subsidiary's Product Dalbavancin for Injection by the U.S. FDA
About this update from Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Announcement on Approval of Subsidiary's Product Dalbavancin for Injection by the U.S. FDAThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment